Orchestra BioMed (NASDAQ:OBIO) Stock: Insider David Pacitti Buys 20,000 Shares

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Director David Pacitti bought 20,000 shares of the company’s stock in a transaction that occurred on Monday, November 9th. The stock was acquired at an average price of $5.00 per share, with a total value of $100,000.00. Following the completion of the purchase, the director directly owned 74,750 shares of the company’s stock, valued at approximately $373,750. The trade was a 36.53% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Orchestra BioMed Stock Up 0.5%

NASDAQ OBIO opened at $5.73 on Wednesday. The business’s 50-day moving average price is $5.77 and its 200 day moving average price is $4.59. Orchestra BioMed Holdings, Inc. has a twelve month low of $3.46 and a twelve month high of $6.50. The company has a current ratio of 8.26, a quick ratio of 8.24 and a debt-to-equity ratio of 1.80.

Orchestra BioMed (NASDAQ:OBIO) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.10. Orchestra BioMed had a negative return on equity of 149.61% and a negative net margin of 184.60%. The firm had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.13 million. Research analysts expect that Orchestra BioMed Holdings, Inc. will post -1.53 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on OBIO. Piper Sandler restated an “overweight” rating on shares of Orchestra BioMed in a report on Thursday, October 15th. Chardan Capital reaffirmed a “buy” rating and set a $20.00 price target on shares of Orchestra BioMed in a research note on Friday, October 23rd. Weiss Ratings raised shares of Orchestra BioMed from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 10th. B. Riley Financial lifted their price target on shares of Orchestra BioMed from $10.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday, September 15th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Orchestra BioMed in a research note on Monday, October 5th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Orchestra BioMed currently has an average rating of “Moderate Buy” and an average target price of $13.17.

Institutional Investors Weigh In On Orchestra BioMed

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rice Hall James & Associates LLC acquired a new position in shares of Orchestra BioMed in the 1st quarter valued at about $81,000. Canada Pension Plan Investment Board purchased a new stake in shares of Orchestra BioMed during the 2nd quarter worth about $91,000. Bank of America Corp DE purchased a new stake in shares of Orchestra BioMed during the 2nd quarter worth about $103,000. AXQ Capital LP purchased a new stake in shares of Orchestra BioMed during the 2nd quarter worth about $110,000. Finally, Algert Global LLC increased its position in Orchestra BioMed by 94.4% during the 2nd quarter. Algert Global LLC now owns 28,486 shares of the company’s stock worth $123,000 after purchasing an additional 13,830 shares in the last quarter. 53.20% of the stock is currently owned by institutional investors and hedge funds.

More Orchestra BioMed News

Here are the key news stories impacting Orchestra BioMed this week:

• Positive Sentiment: The company said its BACKBEAT Global Pivotal Trial of AVIM Therapy completed enrollment with 349 patients, exceeding its target. It plans to submit primary-endpoint data for a late-breaking presentation at Heart Rhythm Society 2027, giving investors a future clinical milestone to watch. Company third-quarter results and business updates
• Positive Sentiment: Several executives and directors bought shares at $5 each on November 9. Purchases included 20,000 shares each by directors David Pacitti and Eric Fain, 5,000 by David Hochman, and 1,000 by CFO Andrew Taylor. Insider buying can signal confidence, though it does not guarantee future performance. Insider purchase report
• Neutral Sentiment: OBIO reported a third-quarter loss of $0.30 per share, narrower than analysts’ expected $0.40 loss and the $0.40 loss a year earlier. However, revenue of $0.09 million missed the $0.13 million consensus estimate, tempering the earnings beat. Q3 earnings report

About Orchestra BioMed

Orchestra BioMed Holdings, Inc. is a clinical-stage biotechnology and medical device company focused on developing technologies for cardiovascular disease and other high-need medical conditions. The company uses a partnership-driven business model, collaborating with established medical device and healthcare companies to advance products through clinical development and toward commercialization. Its lead program is BackBeat Cardiac Neuromodulation Therapy, an investigational bioelectronic treatment intended to provide sustained reductions in blood pressure for patients with hypertension.